



King's Research Portal

DOI:

[10.1017/S0033291717003336](https://doi.org/10.1017/S0033291717003336)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Evans-Lacko, S., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Benjet, C., Bruffaerts, R., Chiu, W. T., Florescu, S., de Girolamo, G., Gureje, O., Haro, J. M., He, Y., Hu, C., Karam, E. G., Kawakami, N., Lee, S., Lund, C., Kovess-Masfety, V., Levinson, D., ... Thornicroft, G. (2018). Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: Results from the WHO World Mental Health (WMH) surveys. *Psychological Medicine*, 48(9), 1560-1571.
<https://doi.org/10.1017/S0033291717003336>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Word count:
Abstract: 248
Text: 4,352
Tables: 5
Figures: 0
Appendix tables: 2

Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: Results from the WHO World Mental Health (WMH) Surveys

S. Evans-Lacko^{1,2}, S. Aguilar-Gaxiola³, A. Al-Hamzawi⁴, J. Alonso⁵, C. Benjet⁶, R. Bruffaerts⁷, W.T. Chiu⁸, S. Florescu⁹, G. de Girolamo¹⁰, O. Gureje¹¹, J. M. Haro¹², Y. He¹³, C. Hu¹⁴, E. G. Karam¹⁵, N. Kawakami¹⁶, S. Lee¹⁷, C. Lund^{1,18}, V. Kovess-Masfety¹⁹, D. Levinson²⁰, F. Navarro-Mateu²¹, B. E. Pennell²², N.A. Sampson⁸, K.M. Scott²³, H. Tachimori²⁴, M. ten Have²⁵, M. C. Viana²⁶, D. R. Williams²⁷, B. J. Wojtyniak²⁸, Z. Zarkov²⁹, R. C. Kessler^{8,*}, S. Chatterji³⁰, G. Thornicroft¹, on behalf of the WHO World Mental Health Survey Collaborators.

September 2017

Author affiliations:

¹Kings College London, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London SE5 8AF, United Kingdom

²PSSRU, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom

³Center for Reducing Health Disparities, UC Davis Health System, Sacramento, California, USA

⁴College of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq

⁵Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Pompeu Fabra University (UPF), Barcelona, Spain; and CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

⁶Department of Epidemiologic and Psychosocial Research, National Institute of Psychiatry Ramón de la Fuente Muniz, Mexico City, Mexico

⁷Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium

⁸Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA

⁹National School of Public Health, Management and Development, Bucharest, Romania

- 38 ¹⁰Unit of Epidemiological and Evaluation Psychiatry, Istituti di Ricovero e Cura a Carattere
39 Scientifico (IRCCS)-St. John of God Clinical Research Centre, Via Pilastroni 4, Brescia, Italy
- 40 ¹¹Department of Psychiatry, University College Hospital, Ibadan, Nigeria
- 41 ¹²Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat,
42 Barcelona, Spain
- 43 ¹³Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine,
44 Shanghai, China
- 45 ¹⁴Shenzhen Institute of Mental Health & Shenzhen Kangning Hospital, Shenzhen, China
- 46 ¹⁵Department of Psychiatry and Clinical Psychology, St George Hospital University Medical
47 Center, Balamand University, Faculty of Medicine, Beirut, Lebanon; Institute for Development,
48 Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon
- 49 ¹⁶Department of Mental Health, School of Public Health, The University of Tokyo, Tokyo, Japan
- 50 ¹⁷Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong
- 51 ¹⁸Alan J Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health,
52 University of Cape Town, South Africa
- 53 ¹⁹Ecole des Hautes Etudes en Santé Publique (EHESP), EA 4057, Paris Descartes University,
54 Paris, France
- 55 ²⁰Mental Health Services, Ministry of Health, Jerusalem, Israel
- 56 ²¹UDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio
57 Murciano de Salud. IMIB-Arrixaca. CIBERESP-Murcia, Murcia, Spain
- 58 ²²Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor,
59 Michigan, USA
- 60 ²³Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand
- 61 ²⁴National Institute of Mental Health, National Center for Neurology and Psychiatry, Kodaira,
62 Tokyo, Japan
- 63 ²⁵Trimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands
- 64 ²⁶Department of Social Medicine, Federal University of Espírito Santo, Vitoria, Brazil
- 65 ²⁷Department of Society, Human Development, and Health, Harvard T.H. Chan School of Public
66 Health, Boston, Massachusetts, USA

²⁸Centre of Monitoring and Analyses of Population Health, National Institute of Public Health-
National Institute of Hygiene, Warsaw, Poland

²⁹Directorate of Mental Health, National Center of Public Health and Analyses, Sofia, Bulgaria

³⁰Department of Information, Evidence and Research, World Health Organization, Geneva,
Switzerland

***Author for correspondence:** Ronald C. Kessler, PhD, Department of Health Care Policy,
Harvard Medical School, 180 Longwood Avenue, Boston, MA USA 02115; 617-432-3587
(voice); 617-432-3588 (fax); Kessler@hcp.med.harvard.edu.

Financial support: The World Health Organization World Mental Health (WMH) Survey
Initiative is supported by the United States National Institute of Mental Health (NIMH; R01
MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the
United States Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558),
the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health
Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and
Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis
Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data
analysis.

The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research
Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological
Study of common mental disorders EPIBUL is supported by the Ministry of Health and the
National Center for Public Health Protection. The Chinese World Mental Health Survey
Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is
supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology,
and Information. The Colombian National Study of Mental Health (NSMH) is supported by the
Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out
and supported jointly by the Center for Excellence on Research in Mental Health (CES
University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the
European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308),
(the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III,
Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE),
Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER
CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted
educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey
(IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct
support from the Iraqi IMHS team with funding from both the Japanese and European Funds
through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National
Health Survey is funded by the Ministry of Health with support from the Israel National Institute
for Health Policy and Health Services Research and the National Insurance Institute of Israel.
The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on
Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-

TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health / Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from, Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia, Servier, UPO. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project Epidemiology of Mental Health and Access to Care –EZOP Project (PL 0256) was supported by Iceland, Liechtenstein and Norway through funding from the EEA Financial Mechanism and the Norwegian Financial Mechanism. EZOP project was co-financed by the Polish Ministry of Health. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The Psychiatric Enquiry to General Population in Southeast Spain – Murcia (PEGASUS-Murcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National Institute of Mental Health (R01-MH61905). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr. Evans-Lacko currently holds a Starting Grant from the European Research Council (337673). Dr. Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust.

154 GT acknowledges financial support from the Department of Health via the National Institute for
155 Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South
156 London and Maudsley NHS Foundation Trust in partnership with King's College London and
157 King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s)
158 and not necessarily those of the NHS, the NIHR or the Department of Health. GT is supported
159 by the European Union Seventh Framework Programme (FP7/2007-2013) Emerald project.
160
161 A complete list of all within-country and cross-national WMH publications can be found at
162 <http://www.hcp.med.harvard.edu/wmh/>.

Abstract

Background: The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. We examine this gap by socio-economic status (SES; indicated by family income and respondent education) and service sector in a cross-national analysis of community epidemiological survey data.

Methods: Data come from 16,753 respondents with 12-month DSM-IV disorders from community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV anxiety, mood, or substance disorders and treatment of these disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI).

Results: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 22.0% in upper-middle-income countries, and 36.8% in high-income countries received treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this was true mostly for specialty mental health treatment, where the association was positive with education (highest treatment among respondents with highest education and a weak association of education with treatment among other respondents) but non-monotonic with income (somewhat lower treatment rates among middle-income respondents and equivalent among those with high and low incomes).

Conclusions: The modest, but nonetheless stronger, association of education than income with treatment raises questions about a financial barriers interpretation of the inverse association of SES with treatment, although future within-country analyses that consider contextual factors might document other important specifications. While beyond the scope of this report, such an expanded analysis could have important implications for designing interventions aimed at increasing mental disorder treatment among socio-economically disadvantaged people.

187

188 **Key words:** Mental disorders, mental health service use, inequalities, education, income,

189 occupation, WMH surveys, population studies

190

Background

The discrepancy between the number of people needing treatment for mental disorders and the number receiving treatment, known as the mental health treatment gap, represents a major public health challenge. Although mental disorders are a leading cause of disability (World Health Organization, 2012; Whiteford *et al.* 2015; Vigo *et al.* 2016), only a minority of people with these disorders receives treatment (Wang *et al.* 2007). This gap is even greater for people with low socio-economic status (SES) and those living in low-income countries (Steele *et al.* 2007; Ormel *et al.* 2008) even adjusting for disorder severity (Mojtabai, 2010; Andrade *et al.* 2014).

It is less clear, though, whether these disparities are equally large across all service sectors and all levels of disorder severity. We know that cross-national differences in treatment rates are strongly influenced by healthcare spending (Lewer *et al.* 2015) and that probability of receiving treatment is influenced by illness severity (Wang *et al.* 2007). We also know that specialist mental health (SMH) treatment resources are scarcer than general medical and nonmedical resources and that access to SMH treatment is often restricted through gatekeepers to the most severe-complex cases (Thornicroft & Tansella, 2013). It is less clear, though, how much the association of SES with treatment varies with these other factors. SES might be more weakly associated with treatment among severe cases or in the SMH sector due to access being driven more by need than ability to pay. Alternatively, it might be that the association of SES with treatment is stronger in these cases due to more stringent barriers associated with low-SES. Research on more general patterns of healthcare utilization suggests that the latter is the case: that is, that under-representation of low-SES individuals is more pronounced in the specialty sector than general medical sector (Devaux & De Looper, 2012), but this pattern might not hold

for mental disorders. Nor do we know how stable such a pattern is across countries, although there is some evidence of cross-national differences in the association of SES with mental disorder treatment (Kessler *et al.* 1997; Van Doorslaer & Masseria, 2004; Devaux & De Looper, 2012).

The World Mental Health (WMH) Surveys (Kessler *et al.* 2009), a series of cross-sectional population surveys of common mental disorders, provide an unprecedented opportunity to investigate the SES gradient in treatment of mental disorders at the level of the individual survey respondent as a joint function of disorder severity, service sector, and country income level. We do this here focusing on mental disorders in the 12 months before interview. It is noteworthy that the cross-national interactions we consider are at the level of the country income group rather than individual country in order to maintain precision in estimating individual-level coefficients. It might be that future analyses could gain more insight by investigating contextual factors other than country income level, but we considered this the most interesting broad factor discriminating WMH countries the current analysis.

Methods

Sample

Data come from the 16,753 respondents across 28 WMH surveys with 12-month DSM-IV disorders. The surveys were administered to representative samples of adult household residents in 25 countries. These include 7 surveys from countries classified by the World bank as lower-middle-income (Colombia, Iraq, Nigeria, Peoples Republic of China, Peru, Ukraine), 7 upper-middle-income (Brazil, Bulgaria, Medellin Colombia [carried out at a later date than the national Colombian survey, at which time the income level of the country had increased], Lebanon, Mexico, Romania, South Africa), and 14 high-income (Belgium, France, Germany,

Israel, Italy, Japan, Netherlands, New Zealand, Northern Ireland, Poland, Portugal, Spain [both a national survey and regional survey in Murcia], USA) (World Bank, 2009). There were no low-income countries in the sample.

The samples were based on a multi-stage clustered area probability household design. Samples were nationally representative in 19 surveys, representative of all urbanized areas in 3 others (Colombia, Mexico, Peru), and representative of selected regions (Nigeria) or Metropolitan areas (Sao Paulo in Brazil, Medellin in Colombia, a series of cities in Japan, Beijing/Shanghai and Shenzhen in the Peoples Republic of China) in the others. More details on sample designs are presented in Appendix Table 1. Interviews were carried out face-to-face in respondents' homes by trained lay interviewers. The respondents considered here were aged 18 and over other than in Medellin (age 19), Japan (age 20), and Israel (age 21). Response rates were 45.9-97.2% across surveys with a weighted (by sample size) average of 70.1% using the American Association for Public Opinion research RR1w definition (AAPOR, 2016).

To reduce respondent burden, interviews were divided into two parts. Part I assessed core mental disorders and was administered to all respondents. Part II assessed additional disorders and correlates and was administered to all Part I respondents with any Part I disorder plus a probability subsample of other Part I respondents. Part II data were weighted to adjust for the under-sampling of Part I non-cases, making weighted Part II prevalence estimates identical to Part I estimates. Treatment was assessed in Part II. 71,239 Part II respondents were interviewed across all surveys, 16,753 of whom met criteria for any 12-month disorders. These 12-month cases are the focus of analysis here. Further details about WMH weighting are available elsewhere (Heeringa *et al.* 2008).

Measures

Mental disorders: Mental disorders were assessed with the WHO Composite

International Diagnostic Interview (CIDI) Version 3.0 (Kessler & Ustun, 2004), a fully-structured interview generating lifetime and 12-month prevalence estimates of common DSM-IV disorders. The 12 disorders considered here include 7 anxiety disorders (adult separation anxiety disorder, agoraphobia, generalized anxiety disorder, panic disorder, post-traumatic stress disorder, social phobia, specific phobia), 3 mood disorders (bipolar disorder including bipolar I, II and sub-threshold; dysthymic disorder; major depressive episode [MDE]), and 2 substance use disorders (abuse or dependence on alcohol or illicit drugs). As detailed elsewhere (Merikangas *et al.* 2011), our definition of sub-threshold bipolar disorder includes both hypomania without history of major depressive episode and sub-threshold hypomania with history of major depressive episode. Our definition of substance dependence is limited to cases with a history of abuse. The CIDI interview translation, back-translation, adaptation, and harmonization protocol required culturally competent bilingual clinicians to review, modify, and approve key phrases describing symptoms (Harkness *et al.* 2008). Blinded clinical reappraisal interviews with the Structured Clinical Interview for DSM-IV (First *et al.* 2002) in a number of WMH surveys found generally good concordance with diagnoses based on the CIDI (Haro *et al.* 2006).

We focus here on disorders present in the 12 months before interview. Respondents were classified as having a severe 12-month disorder if at least one of their DSM-IV/CIDI disorders included either bipolar I disorder, substance dependence with a physiological dependence syndrome, any disorder associated with making a 12-month suicide attempt, or any disorder associated with severe impairment in any domain of the expanded-revised Sheehan Disability scales (SDS) (Leon *et al.* 1997). Respondents not classified severe were classified moderate if at least one of their 12-month disorders included substance dependence without a physiological

dependence syndrome or at least one disorder with moderate interference in any SDS domain.

All other respondents with 12-month disorders were classified as mild (Ten Have *et al.* 2013).

Mental Health Treatment: Part II respondents were asked if they ever obtained professional treatment for “problems with emotions, nerves, mental health, or use of alcohol or drugs” and, if so, whether they received such treatment at any time during the 12 months before interview. Importantly, this question was not disorder-specific, which means that we have no way of knowing which disorders respondents sought treatment for. Respondents who reported 12-month treatment were asked whether they received this treatment during the past 12 months from each of a wide range of treatment providers that were subsequently classified into four categories: (1) *specialist mental health* (SMH; psychiatrist, psychologist, other mental health professional in any setting, social worker or counselor in a mental health specialist treatment setting, used a mental health hotline); (2) *general medical* (GM; primary care doctor, other medical doctor, any other healthcare professional seen in a GM setting); (3) *human services* (HS; religious or spiritual advisor, social worker, or counsellor in any setting other than SMH); and (4) *complementary alternative medicine* (CAM; any other type of healer such as chiropractors or participation in self-help groups). Further details on the treatment variables are presented elsewhere (Wang *et al.* 2007).

Socio-economic status: Two indicators of SES were considered: respondent education and family income in the 12 months before interview. As educational levels and systems varied across countries, education was defined in terms of four groups based on country-specific distributions of *high* (which, in high-income countries, corresponded to a college degree with or without further education), *high-average* (some post-secondary education without a college degree), *low-average* (secondary school graduation), and *low* (less than secondary education,

including no education). More details on the education coding scheme are presented elsewhere (Scott *et al.* 2014). Family income was also divided into four categories using the within-country approach adopted in international studies of welfare economics (Levinson *et al.* 2010), which defines *high income* as greater than three times the within-country median per capita family income (i.e., income divided by number of family members), *high-average* income as between one and three times median per capita family income, *low-average* income as 50-100% of median per capita family income, and *low* income as less than or equal to 50% of median per capita family income.

Control variables: Our models controlled for respondent age, sex, and marital status.

Age was considered in four groups of 18-34, 35-49, 50-64, and 65+. Marital status was divided into three groups of never married, previously married (separated, divorced, widowed), and currently married or cohabiting.

Statistical analysis

Weights adjusted for under-sampling Part I respondents without disorders, differences in within-household probabilities of selection (due to the selection of only one respondent per household no matter the number of eligible residents), and residual discrepancies between sample and population distributions on Census demographic-geographic variables. All multivariable regression models in these weighted data were estimated in pooled cross-national analyses with dummy control variables included for surveys, yielding coefficients representing pooled within-survey associations. Controls were also included for respondent age, sex, and marital status.

The multivariate associations of type, number, and severity of mental disorders with treatment were specified in a relatively complex model, both because these disorder

characteristics are known to predict treatment (Andrade *et al.* 2014) and because SES is known to be inversely related to these disorder characteristics (Scott *et al.* 2014), making it important to control adequately for these characteristics to obtain accurate estimates of effects of SES on treatment. Expanded models then examined both main effects of SES and interactions of SES with disorder severity and country income level. All models were estimated using a logistic link function.

The multivariable associations of mental disorders with treatment in these models were necessarily constrained because the number of logically possible disorder combinations ($2^{12} = 4,096$) is far greater than the number of predictors we could include in the models. As a result, our models included 12 separate disorder-specific dummy variables along with dummy variables for exactly 3 and 4+ disorders. Given that all respondents had at least one disorder and that the model included dummy variables for people with 3+ disorders, the disorder-specific ORs represent the adjusted (for the control variables) incremental predicted odds of treatment (versus not-treatment) among respondents with exactly one disorder. The incremental predictive effects of individual disorders among people with 2 disorders were then assumed to be multiplicative; that is, if the OR associated with Disorder X was 1.5, we would expect respondents with exactly 1 other disorder would have a 1.5 increased odds of obtaining treatment in the presence versus absence of Disorder X. This specification imposed parsimony on the data by constraining the OR of Disorder X to be the same across all 11 combinations of Disorder X with exactly 1 other disorder (i.e., reducing the $12 \times 12 = 144$ logically possible main effects and 2-way interactions between pairs of disorders to 12 coefficients). The dummy variables for 3 and 4+ disorders imposed additional constraints by assuming that the 3-way and higher-order interactions among disorders predicting treatment were subject to a constant multiplier that could be 1.0 (i.e., the

interactions were strictly multiplicative) or different from 1.0. Models of this form have been shown to be useful in a number of prior WMH analyses (e.g., Stein *et al.* 2016; McGrath *et al.* 2016).

Logistic regression coefficients and standard errors were exponentiated to generate odds-ratios (ORs) and 95% confidence intervals (95% CIs). Confidence intervals for prevalence estimates and ORs were estimated using the Taylor series linearization method (Wolter, 1985) implemented in the SUDAAN software system (Research Triangle Institute, 2002) to adjust for weighting and geographic clustering of data. We used design-based F tests to evaluate between country differences in means and design-based Wald χ^2 tests to evaluate the multivariable significance of predictor sets to decide when individually significant coefficients should be interpreted. Significance was consistently evaluated using .05-level two-sided tests. Even with these global tests, though, over-fitting was possible due to the large number of tests, making it important to consider results only exploratory.

Results

Twelve-month treatment of DSM-IV/CIDI disorders

A weighted 14.9% of Part II respondents across surveys met criteria for at least one 12-month DSM-IV/CIDI disorder. More details about between-survey differences and prevalence estimates of individual disorders are reported elsewhere (Scott *et al.* In press). 29.0% of respondents with 12-month disorders received 12-month treatment. The treatment rate was highest in high-income countries (36.8%), lower in upper-middle-income countries (22.0%), and lowest in lower-middle-income countries (13.7%; $F_{2,5366}=221.1$, $p<.001$). (Table 1) The highest treatment rate across surveys was in Murcia, Spain (49.6%) and the lowest in Shenzhen in the People's Republic of China (PRC; 6.7%).

(Table 1 about here)

The GM sector had the highest treatment rate (17.8%). The SMH sector had the second highest treatment rate (13.5%). The treatment rates were much lower in the human services sector (3.7%) and CAM sector (3.7%). The sum of sector-specific treatment rates (38.7/100 respondents) exceeded the 29.0% of individuals with any treatment due to some patients being treated in multiple sectors. Although there was a consistent trend for treatment rates to decrease with country income level within each sector ($F_{2,5366}=132.7$, $p<.001$ for SMH; $F_{2,5366}=231.4$, $p<.001$ for GM; $F_{2,5366}=6.0$, $p=.003$ for HS; $F_{2,5366}=33.2$, $p<.001$ for CAM) as well as overall ($F_{2,5366}=221.1$, $p<.001$), treatment was consistently most common in the GM sector followed by the SMH sector and much lower in the human services and CAM sectors.

Clinical predictors of treatment

Disorder type was significant in predicting treatment in the base multivariate model predicting overall treatment ($\chi^2_{12}=506.1$, $p<.001$) as well as treatment in each service sector ($\chi^2_{12}=36.4-315.1$, $p<.001$). (Table 2) The significant disorder-specific ORs were overwhelmingly greater than 1.0, indicating that comorbidity was associated with increased odds of treatment. Generalized anxiety disorder and PTSD had significantly elevated ORs in all 5 equations (OR=1.4-2.0). Major depressive episodes had significantly elevated ORs in 4 equations (OR=1.5-2.4), the exception being human services treatment. Two disorders had significantly elevated ORs predicting any treatment and treatment in the SMH and GM sectors: panic disorders (OR=2.4-3.4) and agoraphobia (OR=1.6-1.9). Drug use disorder had significantly elevated ORs predicting any treatment and treatment in the SMH and CAM sectors (OR=1.6-1.8). And two disorders, social phobia and bipolar spectrum disorder, had significant ORs predicting treatment in the SMH sector (OR=1.2-1.3). Alcohol use disorder was the only disorder

associated with multiple significantly decreased ORs, which involved any treatment and treatment in the GM and human services sectors (OR=0.6-0.7) indicating that respondents with any other disorder profiles were significantly less likely to obtain treatment in these sectors in the presence than absence of comorbid alcohol use disorder.

(Table 2 about here)

Disorder number was significantly associated with each type of treatment ($\chi^2_2=9.4-11.7$, $p=.003-.009$) due to significantly decreased ORs for 4+ disorders (OR=0.6-0.7). These decreased ORs indicate that the elevated odds of treatment due to comorbidity (i.e., the generally positive sign pattern of disorder-specific ORs) increase at a decreasing rate as comorbidity becomes more complex. Disorder severity, finally, had a significant monotonic relationship with Each treatment outcome ($\chi^2_2=21.3-186.0$, $p<.001$), with severe disorders having highest relative-odds (OR=2.0-2.9) followed by moderate disorders (OR=1.3-1.5) compared to mild disorders.

SES differences in treatment

The 4-category measures of respondent education and income were significantly correlated with each other (polychoric correlation = 0.295, $p = <.001$; see Appendix Table 2 for within-survey distributions and associations). Controlling income, respondent education was significantly and positively associated with treatment overall ($\chi^2_3=17.0$, $p<.001$) and in three service sectors ($\chi^2_3=8.9-32.2$, $p=.030-<.001$), the exception being the GM sector. These significant associations were due to reduced ORs of 0.4-0.8 for respondents in each of the three lower education categories relative to high-education respondents.

(Table 3 about here)

Family income, in comparison, while not significant overall in predicting any treatment in a model that controlled for education ($\chi^2_3=4.3$, $p=.233$), was significantly and positively

associated with SMH treatment ($\chi^2_3=8.0$, $p=.045$) due to an OR of 0.8 for respondents in each of the three lower income categories relative to the highest income category. In addition, income had a significant inverse association with HS treatment ($\chi^2_3=9.4$, $p=.024$) due to elevated ORs for respondents in each of the two lowest income categories (OR=1.5-1.7) relative to the highest income category.

Interactions of SES with disorder severity, respondent SES, and country income level

Significance of interactions: We estimated interactions of SES with disorder severity and country income level in predicting any treatment and treatment in the SMH and GM sectors. We lacked the statistical power to carry out parallel analyses of interactions predicting HS and CAM treatment. The 3-way interactions were significant for both education and income predicting any treatment ($\chi^2_{12}=22.9-29.8$, $p=.029-.003$) and for income predicting GM treatment ($\chi^2_{12}=26.8$, $p=.008$). The 2-way interactions of income with severity and with country income level were significant in a model that excluded the 3-way interactions in predicting SMH treatment ($\chi^2_6=12.9-13.6$, $p=.045-.035$).

(Table 4 about here)

Education: Subgroup analysis showed that the significant association of education with any treatment in the total sample was limited to severe and moderate cases in high-income countries ($\chi^2_3=9.9-17.2$, $p=.019-.001$). Significant ORs among respondents with lower levels of education were in the range 0.5-0.8. (Table 4) The significant association of education with SMH treatment in the total sample varied by disorder severity and country income, with significant ORs among respondents of lower education were in the range 0.6-0.7. The non-significant association of education with GM treatment found in the total sample was found not to vary significantly by disorder severity or country income.

(Table 5 about here)

Income: Subgroup analysis showed that the non-significant association of income with any treatment in the total sample masked a significantly positive association among severe cases in lower-middle income countries (significant ORs of 0.2-0.4 among respondents in lower income subgroups; $\chi^2_3=20.1$, $p<.001$) and a significantly negative association among mild cases in upper-middle-income countries (a significant OR=1.8 for low-income respondents; $\chi^2_3=14.9$, $p=.002$). (Table 5) The significant association of income with SMH treatment in the total sample was consistent across country income groups due to especially low odds of treatment in intermediate income groups within each severity subsample (OR=0.3-0.5) rather than in the lowest income group (OR=0.7-0.9). The non-significant association of income with GM treatment in the total sample, finally, was found to mask a significantly positive association among moderately severe cases in lower-middle income countries and mild cases in both lower-middle and high income countries (significant ORs of 0.2-0.7; $\chi^2_3=8.8-18.3$, $p=.032-<.001$) and significantly negative associations among mild cases in upper-middle-income countries and severe cases in high income countries (significant ORs of 1.5-2.0; $\chi^2_3=15.1-44.3$, $p=.002-<.001$).

Discussion

These results represent the most comprehensive examination ever undertaken of the associations of SES with mental disorder treatment. Consistent with previous research (Kohn *et al.* 2004; Wang *et al.* 2007; Ormel *et al.* 2008), only a minority of people with the 12-month disorders considered here received any treatment, the highest proportion of people receiving treatment was in the general medical sector followed by the specialty mental health sector, and treatment was much less common in lower- than higher-income countries. However, the two

SES indicators considered here, respondent education and family income, were much less consistently associated with 12-month treatment than we had anticipated.

As noted in the introduction, we had expected to find the association of SES with specialty treatment to increase with disorder severity to the extent that the restrictions on access to specialty care were related to income but to decrease with disorder severity to the extent that the restrictions were related to need for treatment. We found neither pattern, as the lowest odds of SMH treatment were among respondents having intermediate income levels across all levels of disorder severity and country income groups. This could be due to lowest-income people, but not people with intermediate income levels, having free access to specialty care, resulting in highest financial barriers existing among people with intermediate incomes.

The association of education with SMH treatment was stable across all levels of disorder severity and country income groups, with the significant association due to a comparatively high odds of treatment among people at the highest education level (ORs of 0.6-0.7 for lower education levels equivalent to 1.4-1.7 higher odds at highest versus lower levels). These associations are presumably not due to financial barriers given that they were obtained after controlling income. Other possible explanatory variables (e.g., recognition of need, perceived stigma, perceived efficacy of treatment) need to be explored in future studies to interpret these associations.

Subgroup analysis found no significant association of income with overall treatment in the total sample and only inconsistent opposite-sign associations in subsamples. However, the significant positive association with specialty mental health treatment and the significant inverse association with human services treatment in the total sample showed that even though people of different financial means were equally likely to receive some type of treatment, a significant

discrepancy existed in the sector in which treatment was received. This discrepancy was small, though, as cases in the highest income category (roughly one-fourth of the population) had only about 25% higher odds of specialty mental health treatment than those in lower income categories and, as noted in the prior paragraph, there were no differences in odds of receiving specialty treatment across the lower three income categories.

Although the association of income with GM treatment was non-significant in the total sample, a significant 3-way interaction was found due to a series of opposite-sign subgroup associations that had no apparent patterning. Perhaps the clearest observation about this specification is that it showed that lowest income was for the most part not associated with lowest odds of GM treatment. Education, in comparison, was most consistently associated with SMH treatment, as the associations of education with treatment in other service sectors were relatively weak (significant ORs in the range 0.6-0.8).

Why did we find weaker and less consistent associations of income and education with treatment than previous studies (Rossi *et al.* 2005; Tello *et al.* 2005; Steele *et al.* 2007)? One possibility is that we included two indicators of SES in the models, income and education. Given that these two indicators are significantly correlated with each other, the strength of each as a predictor of treatment was reduced by including both in the equations. We considered it appropriate to include both, though, as the mechanisms involved in the two are presumably different. As we saw, both indicators were statistically significant, albeit not large in substantive terms

Limitations

The study had a number of limitations. First, the sample was limited in that the sample of countries was non-representative and the response rate varied widely across countries. Although

we attempted to control for differential response through post-stratification adjustments, survey response might have been related to social status, presence and severity of mental disorders or treatment in ways that were uncorrected.

Second, the disorder measures were limited in that some severe disorders, such as schizophrenia, were not assessed, duration was not measured for the disorders that were assessed, and validity, although good in the WMH surveys where it was assessed (Haro *et al.* 2006), was not assessed in all surveys and might have varied with SES.

Third, the treatment measures were limited to self-reports, which have been found to over-estimate treatment compared to administrative records (Rhodes & Fung, 2004). In addition, these self-reports only assessed number of visits rather than treatment quality. The small amount of research that exists on mental disorder treatment quality finds that low-SES patients are significantly more likely than other patients to receive lower-quality treatment (Amaddeo & Jones, 2007; Young & Rabiner, 2015).

Fourth, the only contextual variable considered was a simple 3-category measure of country income level. Many other potentially important contextual variables exist at both the country level (e.g., access to universal healthcare) and within countries (e.g., number of treatment providers per capita within the access area of the respondent). However, as the number of countries was small ($n = 25$) and no information was available about within-country geographic characteristics in most surveys, we had too few geographic units of analysis to carry out quantitative analyses of other contextual factors. It might be that future analyses could gain more insight by estimating within-country models that treated each country as a case study and considering contextual factors qualitatively.

Conclusions

Within the context of these limitations, our findings are consistent with previous research in showing that only a minority of people with common mental disorders receive treatment, even in high income countries, and that treatment rates are lower in lower income countries. We also broadly confirmed previous evidence that people with low SES have an especially low rate of treatment, although in the total sample this was true only for SMH treatment and income was inversely related to HS treatment, resulting in income being related more to sector of treatment than to whether or not treatment was received. The significant associations of SES with treatment were most consistent in predicting SMH treatment, but they were less strong than anticipated. Direct investigation of reports about barriers to treatment would be needed to delve more deeply into these patterns.

547

Acknowledgments

548 **Financial support:** The World Health Organization World Mental Health (WMH) Survey
549 Initiative is supported by the United States National Institute of Mental Health (NIMH; R01
550 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the
551 United States Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558),
552 the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health
553 Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and
554 Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis
555 Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data
556 analysis.

557 The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research
558 Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological
559 Study of common mental disorders EPIBUL is supported by the Ministry of Health and the
560 National Center for Public Health Protection. The Chinese World Mental Health Survey
561 Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is
562 supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology,
563 and Information. The Colombian National Study of Mental Health (NSMH) is supported by the
564 Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out
565 and supported jointly by the Center for Excellence on Research in Mental Health (CES
566 University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the
567 European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308),
568 (the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III,
569 Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE),

570 Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER
571 CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted
572 educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey
573 (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct
574 support from the Iraqi IMHS team with funding from both the Japanese and European Funds
575 through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National
576 Health Survey is funded by the Ministry of Health with support from the Israel National Institute
577 for Health Policy and Health Services Research and the National Insurance Institute of Israel.
578 The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on
579 Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-
580 TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry
581 of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs
582 Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the
583 WHO (Lebanon), National Institute of Health / Fogarty International Center (R03 TW006481-
584 01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from,
585 Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck,
586 Novartis, OmniPharma, Pfizer, Phenicia, Servier, UPO. The Mexican National Comorbidity
587 Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente
588 (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-
589 G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). Te
590 Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New
591 Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The
592 Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO

593 (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern
594 Ireland Study of Mental Health was funded by the Health & Social Care Research &
595 Development Division of the Public Health Agency. The Peruvian World Mental Health Study
596 was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish
597 project Epidemiology of Mental Health and Access to Care –EZOP Project (PL 0256) was
598 supported by Iceland, Liechtenstein and Norway through funding from the EEA Financial
599 Mechanism and the Norwegian Financial Mechanism. EZOP project was co-financed by the
600 Polish Ministry of Health. The Portuguese Mental Health Study was carried out by the
601 Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with
602 collaboration of the Portuguese Catholic University, and was funded by Champalimaud
603 Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and
604 Ministry of Health. The Romania WMH study projects "Policies in Mental Health Area" and
605 "National Study regarding Mental Health and Services Use" were carried out by National School
606 of Public Health & Health Services Management (former National Institute for Research &
607 Development in Health), with technical support of Metro Media Transilvania, the National
608 Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL,
609 Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health)
610 with supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study
611 (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and
612 National Institute of Drug Abuse with supplemental funding from the South African Department
613 of Health and the University of Michigan. The Psychiatric Enquiry to General Population in
614 Southeast Spain – Murcia (PEGASUS-Murcia) Project has been financed by the Regional Health
615 Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social)

and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr. Evans-Lacko currently holds a Starting Grant from the European Research Council (337673). Dr. Thornicroft is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. GT acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. GT is supported by the European Union Seventh Framework Programme (FP7/2007-2013) Emerald project.

A complete list of all within-country and cross-national WMH publications can be found at <http://www.hcp.med.harvard.edu/wmh/>.

Conflict of Interest: Dr. Evans-Lacko received consulting fees from Lundbeck, not connected to this research. In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona

639 Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out
640 healthcare research. The remaining authors declare no conflicts of interest.

641 **Ethical standards:** The authors assert that all procedures contributing to this work comply with
642 the ethical standards of the relevant national and institutional committees on human
643 experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

644

645 **Group information:** The WHO World Mental Health Survey collaborators are Sergio Aguilar-
646 Gaxiola, MD, PhD, Ali Al-Hamzawi, MD, Mohammed Salih Al-Kaisy, MD, Jordi Alonso, MD,
647 PhD, Laura Helena Andrade, MD, PhD, Corina Benjet, PhD, Guilherme Borges, ScD, Evelyn J.
648 Bromet, PhD, Ronny Bruffaerts, PhD, Brendan Bunting, PhD, Jose Miguel Caldas de Almeida,
649 MD, PhD, Graça Cardoso, MD, PhD, Somnath Chatterji, MD, Alfredo H. Cia, MD, Louisa
650 Degenhardt, PhD, Koen Demyttenaere, MD, PhD, John Fayyad, MD, Silvia Florescu, MD, PhD,
651 Giovanni de Girolamo, MD, Oye Gureje, MD, DSc, FRCPsych, Josep Maria Haro, MD, PhD,
652 Yanling He, MD, Hristo Hinkov, MD, PhD, Chi-yi Hu, MD, PhD, Yueqin Huang, MD, MPH,
653 PhD, Peter de Jonge, PhD, Aimee Nasser Karam, PhD, Elie G. Karam, MD, Norito Kawakami,
654 MD, DMSc, Ronald C. Kessler, PhD, Andrzej Kiejna, MD, PhD, Viviane Kovess-Masfety, MD,
655 PhD, Sing Lee, MB, BS, Jean-Pierre Lepine, MD, Daphna Levinson, PhD, John McGrath, MD,
656 PhD, Maria Elena Medina-Mora, PhD, Jacek Moskalewicz, PhD, Fernando Navarro-Mateu, MD,
657 PhD, Beth-Ellen Pennell, MA, Marina Piazza, MPH, ScD, Jose Posada-Villa, MD, Kate M.
658 Scott, PhD, Tim Slade, PhD, Juan Carlos Stagnaro, MD, PhD, Dan J. Stein, FRCPC, PhD,
659 Margreet ten Have, PhD, Yolanda Torres, MPH, Dra.HC, Maria Carmen Viana, MD, PhD,
660 Harvey Whiteford, MBBS, PhD, David R. Williams, MPH, PhD, Bogdan Wojtyniak, ScD.

661

662 **Disclaimer:** None of the funders had any role in the design, analysis, interpretation of results, or
663 preparation of this paper. The views and opinions expressed in this report are those of the authors
664 and should not be construed to represent the views of the World Health Organization, other
665 sponsoring organizations, agencies, or governments.

References

- Amaddeo F, Jones J** (2007). What is the impact of socio-economic inequalities on the use of mental health services? *Epidemiologia e Psichiatria Sociale* **16**, 16-9.
- American Association for Public Opinion Research (AAPOR). 2016.** *Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 9th edition.* AAPOR. (http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf). Accessed 31 August 2017.
- Andrade LH, Alonso J, Mneimneh Z, Wells JE, Al-Hamzawi A, Borges G, Bromet E, Bruffaerts R, de Girolamo G, de Graaf R, Florescu S, Gureje O, Hinkov HR, Hu C, Huang Y, Hwang I, Jin R, Karam EG, Kovess-Masfety V, Levinson D, Matschinger H, O'Neill S, Posada-Villa J, Sagar R, Sampson NA, Sasu C, Stein DJ, Takeshima T, Viana MC, Xavier M, Kessler RC** (2014). Barriers to mental health treatment: results from the WHO World Mental Health surveys. *Psychological Medicine* **44**, 1303-17.
- Chen H, Cohen P, Chen S** (2010). How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. *Communications in Statistics—Simulation and Computation*® **39**, 860-864.
- Devaux M, De Looper M** (2012). Income-related inequalities in health service utilisation in 19 OECD countries, 2008-2009, OECD Health Working Papers, No. 58. OECD Publishing: Paris, France. (DOI: 10.1787/5k95xd6stnxt-en). Accessed 31 May 2017.

686 **First MB, Spitzer RL, Gibbon M, Williams JBW** (2002). *Structured Clinical Interview for*
687 *DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP)*. Biometrics
688 Research, New York State Psychiatric Institute: New York.

689 **Harkness J, Pennell B-E, Villar A, Gebler N, Aguilar-Gaxiola S, Bilgen I** (2008). Translation
690 procedures and translation assessment in the World Mental Health Survey Initiative. In *The*
691 *WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental*
692 *Disorders* (ed. R. C. Kessler and T. B. Üstün), pp. 91-113. Cambridge University Press: New
693 York, NY.

694 **Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de Girolamo G, Guyer ME, Jin R, Lepine**
695 **JP, Mazzi F, Reneses B, Vilagut G, Sampson NA, Kessler RC** (2006). Concordance of the
696 Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical
697 assessments in the WHO World Mental Health surveys. *International Journal of Methods in*
698 *Psychiatric Research* **15**, 167-80.

699 **Heeringa SG, Wells JE, Hubbard F, Mneimneh ZN, Chiu WT, Sampson NA, Berglund PA**
700 (2008). Sample designs and sampling procedures. In *The WHO World Mental Health Surveys:*
701 *Global Perspectives on the Epidemiology of Mental Disorders* (ed. R. C. Kessler and T. B.
702 Üstün), pp. 14-32. Cambridge University Press: New York, NY.

703 **Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ustun TB** (2009). The WHO
704 World Mental Health (WMH) Surveys. *Die Psychiatrie : Grundlagen und Perspektiven* **6**, 5-9.

705 **Kessler RC, Frank RG, Edlund M, Katz SJ, Lin E, Leaf P** (1997). Differences in the use of
706 psychiatric outpatient services between the United States and Ontario. *New England Journal of*
707 *Medicine* **336**, 551-7.

708 **Kessler RC, Ustun TB** (2004). The World Mental Health (WMH) Survey Initiative Version of
709 the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI).
710 *International Journal of Methods in Psychiatric Research* **13**, 93-121.

711 **Kohn R, Saxena S, Levav I, Saraceno B** (2004). The treatment gap in mental health care.
712 *Bulletin of the World Health Organization* **82**, 858-66.

713 **Leon AC, Olfson M, Portera L, Farber L, Sheehan DV** (1997). Assessing psychiatric
714 impairment in primary care with the Sheehan Disability Scale. *International Journal of*
715 *Psychiatry in Medicine* **27**, 93-105.

716 **Levinson D, Lakoma MD, Petukhova M, Schoenbaum M, Zaslavsky AM, Angermeyer M,**
717 **Borges G, Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, Haro JM, Hu C, Karam**
718 **AN, Kawakami N, Lee S, Lepine JP, Browne MO, Okoliyski M, Posada-Villa J, Sagar R,**
719 **Viana MC, Williams DR, Kessler RC** (2010). Associations of serious mental illness with
720 earnings: results from the WHO World Mental Health surveys. *British Journal of Psychiatry*
721 **197**, 114-21.

722 **Lewer D, O'Reilly C, Mojtabai R, Evans-Lacko S** (2015). Antidepressant use in 27 European
723 countries: associations with sociodemographic, cultural and economic factors. *British Journal of*
724 *Psychiatry* **207**, 221-6.

725 **McGrath JJ, Saha S, Al-Hamzawi A, Andrade L, Benjet C, Bromet EJ, Browne MO,**
 726 **Caldas de Almeida JM, Chiu WT, Demyttenaere K, Fayyad J, Florescu S, de Girolamo G,**
 727 **Gureje O, Haro JM, Ten Have M, Hu C, Kovess-Masfety V, Lim CC, Navarro-Mateu F,**
 728 **Sampson N, Posada-Villa J, Kendler KS, Kessler RC** (2016). The bidirectional associations
 729 between psychotic experiences and DSM-IV mental disorders. *American Journal of Psychiatry*
 730 **10**, 997-1006.

731 **Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH,**
 732 **Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE,**
 733 **Zarkov Z** (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental
 734 health survey initiative. *Archives of General Psychiatry* **68**, 241-51.

735 **Mojtabai R** (2010). Mental illness stigma and willingness to seek mental health care in the
 736 European Union. *Social Psychiatry and Psychiatric Epidemiology* **45**, 705-12.

737 **Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Bromet**
 738 **EJ, Burger H, Demyttenaere K, de Girolamo G, Haro JM, Hwang I, Karam E, Kawakami**
 739 **N, Lepine JP, Medina-Mora ME, Posada-Villa J, Sampson N, Scott K, Ustun TB, Von**
 740 **Korff M, Williams DR, Zhang M, Kessler RC** (2008). Disability and treatment of specific
 741 mental and physical disorders across the world. *British Journal of Psychiatry* **192**, 368-75.

742 **Rhodes AE, Fung K** (2004). Self-reported use of mental health services versus administrative
 743 records: care to recall? *International Journal of Methods in Psychiatric Research* **13**, 165-75.

744 **Rossi A, Amaddeo F, Sandri M, Tansella M** (2005). Determinants of once-only contact in a
 745 community-based psychiatric service. *Social Psychiatry and Psychiatric Epidemiology* **40**, 50-6.

746 **Scott KM, Al-Hamzawi AO, Andrade LH, Borges G, Caldas-de-Almeida JM, Fiestas F,**
747 **Gureje O, Hu C, Karam EG, Kawakami N, Lee S, Levinson D, Lim CC, Navarro-Mateu F,**
748 **Okoliyski M, Posada-Villa J, Torres Y, Williams DR, Zakhozha V, Kessler RC (2014).**
749 Associations between subjective social status and DSM-IV mental disorders: results from the
750 World Mental Health surveys. *JAMA Psychiatry* **71**, 1400-8.

751 **Research Triangle Institute (2002).** *SUDAAN: Professional Software for Survey Data Analysis*
752 [computer program]. Research Triangle Institute: Research Triangle Park, NC.

753 **Scott KM, de Jonge P, Stein DJ, Kessler RC eds. (In press).** *Mental Disorders Around the*
754 *World: Facts and Figures from the World Mental Health Surveys.* Cambridge University Press:
755 New York, NY.

756 **Steele L, Dewa C, Lee K (2007).** Socioeconomic status and self-reported barriers to mental
757 health service use. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie* **52**, 201-6.

758 **Stein DJ, Karam EG, Shahly V, Hill ED, King A, Petukhova M, Atwoli L, Bromet EJ,**
759 **Florescu S, Haro JM, Hinkov H, Karam A, Medina-Mora ME, Navarro-Mateu F, Piazza**
760 **M, Shalev A, Torres Y, Zaslavsky AM, Kessler RC. (2016).** Post-traumatic stress disorder
761 associated with life-threatening motor vehicle collisions in the WHO World Mental Health
762 Surveys. *BMC Psychiatry.* **16**, 257-71.

763 **Tello JE, Mazzi M, Tansella M, Bonizzato P, Jones J, Amaddeo F (2005).** Does
764 socioeconomic status affect the use of community-based psychiatric services? A South Verona
765 case register study. *Acta Psychiatrica Scandinavica* **112**, 215-23.

766 **Ten Have M, Nuyen J, Beekman A, de Graaf R** (2013). Common mental disorder severity and
767 its association with treatment contact and treatment intensity for mental health problems.
768 *Psychological Medicine* **43**, 2203-13.

769 **Thornicroft G, Tansella M** (2013). The balanced care model for global mental health.
770 *Psychological Medicine* **43**, 849-63.

771 **Van Doorslaer E, Masseria C** (2004). OECD health working paper NO. 14, Income-related
772 inequality in the use of medical care in 21 OECD countries. OECD Publishing: Paris, France.
773 (<https://www.oecd.org/els/health-systems/31743034.pdf>). Accessed 31 May 2017.

774 **Vigo D, Thornicroft G, Atun R** (2016). Estimating the true global burden of mental illness.
775 *Lancet Psychiatry* **3**, 171-8.

776 **Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, Bruffaerts**
777 **R, de Girolamo G, de Graaf R, Gureje O, Haro JM, Karam EG, Kessler RC, Kovess V,**
778 **Lane MC, Lee S, Levinson D, Ono Y, Petukhova M, Posada-Villa J, Seedat S, Wells JE**
779 (2007). Use of mental health services for anxiety, mood, and substance disorders in 17 countries
780 in the WHO world mental health surveys. *Lancet* **370**, 841-50.

781 **Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T** (2015). The global burden of
782 mental, neurological and substance use disorders: an analysis from the Global Burden of Disease
783 Study 2010. *PloS One* **10**, e0116820.

784 **Wolter KM** (1985). *Introduction to Variance Estimation*. Springer-Verlag: New York, NY.

785 **World Bank** (2009). World Bank list of economies (July 2009). The World Bank: Washington,
786 D.C. (http://www.iqla.org/joining/World-Bank_Classification-List_2009.pdf). Accessed 31 May
787 2017.

788 **World Health Organization** (2012). Global burden of mental disorders and the need for a
789 comprehensive, coordinated response from health and social sectors at the country level.
790 Document EB130.R8. World Health Organization: Geneva, Switzerland.
791 (http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_R8-en.pdf). Accessed 31 May 2017.

792 **Young AS, Rabiner D** (2015). Racial/ethnic differences in parent-reported barriers to accessing
793 children's health services. *Psychological Services* **12**, 267-73.

Table 1. Twelve-month treatment of mental disorders overall and within separate service sectors among WMH respondents with 12-month DSM-IV/CIDI disorders by survey

	Any treatment		Specialty mental health		General medical		Human services		CAM		Number of respondents with any disorder
	%	(SE)	%	(SE)	%	(SE)	%	(SE)	%	(SE)	(n)
I. Lower-middle income countries											
Colombia	13.5	(1.6)	7.4	(1.2)	5.8	(1.0)	1.1	(0.6)	0.5	(0.3)	(789)
Iraq	11.7	(2.3)	3.6	(1.6)	4.1	(1.4)	4.6	(1.5)	0.5	(0.4)	(469)
Nigeria	11.7	(2.5)	1.5	(0.8)	10.3	(2.5)	1.3	(0.7)	0.0	(0.0)	(204)
PRC-Beijing/Shanghai	12.1	(4.5)	3.7	(1.5)	8.5	(4.4)	0.3	(0.3)	4.8	(4.0)	(206)
PRC-Shenzhen	6.7	(1.6)	2.4	(1.0)	2.6	(0.9)	1.1	(0.7)	2.4	(0.8)	(404)
Peru	19.1	(2.6)	10.3	(1.4)	5.4	(1.4)	2.7	(0.8)	2.9	(0.9)	(360)
Ukraine	18.1	(2.3)	4.0	(1.0)	11.1	(1.9)	3.8	(1.0)	1.5	(0.5)	(643)
Overall	13.7	(0.9)	5.1	(0.6)	6.4	(0.6)	2.6	(0.5)	1.3	(0.3)	(3,075)
II. Upper-middle income countries											
Brazil-Sao Paulo	24.1	(1.0)	15.5	(1.1)	8.8	(0.8)	3.5	(0.7)	3.4	(0.6)	(1,177)
Bulgaria	20.7	(2.7)	6.4	(1.2)	16.8	(2.5)	0.9	(0.8)	0.05	(0.05)	(400)
Colombia-Medellin	18.7	(2.1)	11.7	(1.5)	6.9	(1.4)	1.4	(0.6)	1.6	(0.6)	(514)
Lebanon	11.0	(1.8)	3.4	(1.1)	7.2	(1.4)	1.2	(0.6)	0.0	(0.0)	(309)
Mexico	18.0	(1.8)	10.3	(1.5)	6.1	(1.0)	0.6	(0.3)	3.1	(1.0)	(655)
Romania	23.4	(3.0)	11.2	(2.3)	13.5	(2.7)	0.8	(0.5)	0.0	(0.0)	(175)
South Africa	25.7	(2.5)	5.8	(1.3)	16.9	(1.9)	6.4	(1.4)	5.8	(1.0)	(700)
Overall	22.0	(0.9)	10.0	(0.6)	11.3	(0.7)	3.2	(0.5)	3.1	(0.3)	(3,930)
III. High income countries											
Belgium	38.3	(4.2)	20.2	(2.8)	30.7	(4.9)	0.9	(0.7)	1.2	(0.6)	(227)
France	30.5	(2.9)	11.9	(1.6)	23.1	(2.6)	1.5	(0.7)	1.1	(0.6)	(394)
Germany	25.8	(3.3)	13.5	(2.4)	17.5	(2.7)	1.9	(0.8)	1.2	(0.5)	(268)
Israel	34.9	(2.3)	17.5	(1.8)	17.3	(1.9)	5.7	(1.1)	3.1	(0.8)	(483)
Italy	26.7	(2.7)	8.5	(2.2)	22.7	(2.5)	1.2	(0.5)	0.6	(0.4)	(280)
Japan	22.9	(3.3)	15.3	(2.5)	11.2	(2.1)	1.3	(0.7)	5.5	(2.2)	(237)
Netherlands	30.5	(4.4)	16.2	(2.9)	24.3	(4.2)	1.7	(0.7)	2.3	(0.8)	(273)
New Zealand	38.4	(1.2)	16.1	(1.0)	28.4	(1.0)	4.9	(0.5)	6.5	(0.7)	(2,734)
Northern Ireland	42.5	(3.0)	14.8	(1.8)	38.1	(2.8)	2.7	(0.7)	6.2	(1.4)	(533)
Poland	21.5	(2.0)	13.5	(1.4)	10.1	(1.2)	2.6	(0.8)	3.7	(0.9)	(622)
Portugal	36.2	(2.0)	17.6	(1.7)	24.0	(1.7)	2.1	(0.6)	1.7	(0.4)	(726)
Spain	34.4	(3.1)	20.5	(2.3)	23.1	(2.4)	1.0	(0.5)	1.6	(0.6)	(407)
Spain-Murcia	49.6	(3.4)	28.0	(4.2)	26.9	(2.6)	0.0	(0.0)	1.0	(0.6)	(361)
USA	41.6	(0.9)	22.0	(0.9)	23.1	(0.8)	8.1	(0.8)	6.9	(0.6)	(2,203)
Overall	36.8	(0.6)	17.7	(0.5)	24.2	(0.5)	4.3	(0.3)	4.6	(0.3)	(9,748)
IV. Total											
	29.0	(0.5)	13.5	(0.3)	17.8	(0.4)	3.7	(0.2)	3.7	(0.2)	(16,753)
F _{2,5366}	221.1*		132.7*		231.4*		6.0*		33.2*		

*Significant difference across the three country income groups at the .05 level, two-sided test

Table 2. Multivariable associations of clinical characteristics (disorder type, number, and severity) with 12-month treatment of mental disorders overall and within separate service sectors among WMH respondents with 12-month DSM-IV/CIDI disorders (n=16,753)¹

	Any treatment		Specialty mental health		General medical		Human services		CAM	
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)
I. Type of disorder										
a. Anxiety										
Adult separation anxiety disorder	1.1	(0.8-1.4)	1.2	(0.9-1.6)	0.9	(0.7-1.2)	1.2	(0.7-2.0)	1.1	(0.7-1.7)
Agoraphobia (w/o panic disorder)	1.8*	(1.4-2.2)	1.6*	(1.2-2.1)	1.9*	(1.5-2.5)	0.8	(0.5-1.4)	1.0	(0.7-1.5)
Generalized anxiety disorder	1.8*	(1.5-2.0)	1.6*	(1.3-1.9)	1.7*	(1.4-2.0)	1.5*	(1.1-2.0)	1.4*	(1.1-1.9)
Panic disorder	3.4*	(2.8-4.0)	2.4*	(1.9-2.9)	3.2*	(2.6-3.8)	1.4	(1.0-2.0)	1.4	(0.9-2.0)
Posttraumatic stress disorder	2.0*	(1.7-2.4)	1.7*	(1.4-2.1)	1.7*	(1.5-2.1)	1.4*	(1.0-2.0)	1.7*	(1.2-2.3)
Social phobia	1.1	(1.0-1.3)	1.2*	(1.0-1.5)	1.1	(1.0-1.3)	1.1	(0.8-1.6)	1.1	(0.9-1.5)
Specific phobia	0.9*	(0.7-1.0)	0.8	(0.7-1.0)	0.9	(0.8-1.1)	0.8	(0.6-1.1)	1.0	(0.8-1.3)
b. Mood										
Bipolar spectrum disorder	1.2	(0.9-1.4)	1.3*	(1.1-1.7)	1.2	(0.9-1.5)	1.2	(0.9-1.7)	0.9	(0.6-1.3)
Dysthymic disorder	1.3*	(1.1-1.6)	1.1	(0.9-1.4)	1.2	(1.0-1.5)	1.1	(0.8-1.6)	0.7	(0.5-1.1)
Major depressive episode	2.2*	(1.9-2.5)	2.4*	(2.0-2.8)	1.9*	(1.7-2.3)	1.2	(0.9-1.7)	1.5*	(1.1-2.1)
c. Substance										
Alcohol abuse or dependence	0.7*	(0.6-0.9)	1.0	(0.8-1.3)	0.6*	(0.5-0.8)	0.7*	(0.4-1.0)	0.9	(0.6-1.4)
Drug abuse or dependence	1.6*	(1.2-2.2)	1.6*	(1.2-2.1)	1.4	(0.9-2.0)	1.0	(0.6-1.8)	1.8*	(1.1-3.0)
χ^2_{12}	506.1*		275.1*		315.1*		39.4*		36.4*	
II. Number of disorders										
4+	0.7*	(0.5-1.0)	0.6*	(0.4-0.9)	0.6*	(0.4-0.9)	1.1	(0.5-2.1)	1.1	(0.6-2.1)
3	1.1	(0.9-1.3)	1.0	(0.8-1.3)	1.0	(0.8-1.2)	1.1	(0.7-1.7)	1.3	(0.9-1.9)
2	1.0	--	1.0	--	1.0	--	1.0	--	1.0	--
χ^2_2	11.0*		11.7*		9.4*		0.1		1.9	
III. Severity of disorders										
Severe	2.4*	(2.1-2.8)	2.9*	(2.4-3.4)	2.1*	(1.8-2.5)	2.0*	(1.5-2.7)	2.4*	(1.8-3.3)
Moderate	1.3*	(1.2-1.5)	1.3*	(1.1-1.6)	1.4*	(1.2-1.6)	1.3	(1.0-1.8)	1.5*	(1.1-2.0)
Mild	1.0	--	1.0	--	1.0	--	1.0	--	1.0	--
χ^2_2	179.6*		186.0*		90.6*		21.3*		36.6*	

*Significant at the .05 level, two-sided test

¹Results are based on multivariable logistic regression models with dummy variables for survey. See the section on Analysis Methods in the text for a discussion of the logic of the models and interpretation of coefficients.

Table 3. Multivariable associations of socio-demographic characteristics with 12-month treatment of mental disorders overall and within separate service sectors controlling for clinical characteristics among WMH respondents with 12-month DSM-IV/CIDI disorders (n=16,753)¹

	Level of education									Level of family income								
	Low		Low average		High average		High		χ^2_3	Low		Low average		High average		High		χ^2_3
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)		OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	
I. Any treatment	0.8*	(0.7-0.9)	0.8*	(0.7-0.9)	0.8*	(0.7-1.0)	1.0	--	17.0*	0.9	(0.8-1.1)	0.9	(0.8-1.0)	0.9	(0.8-1.0)	1.0	--	4.3
II. Specialty mental health care	0.6*	(0.5-0.8)	0.6*	(0.5-0.7)	0.7*	(0.6-0.9)	1.0	--	32.2*	0.8*	(0.7-1.0)	0.8*	(0.7-0.9)	0.8*	(0.7-1.0)	1.0	--	8.0*
III. General medical	1.0	(0.8-1.2)	0.9	(0.8-1.1)	1.0	(0.8-1.2)	1.0	--	0.6	1.0	(0.8-1.1)	0.9	(0.8-1.1)	0.9	(0.8-1.1)	1.0	--	1.3
IV. Human services	0.6*	(0.4-0.8)	0.8	(0.6-1.1)	0.8	(0.6-1.1)	1.0	--	8.9*	1.5*	(1.0-2.1)	1.7*	(1.2-2.4)	1.3	(0.9-1.9)	1.0	--	9.4*
V. CAM	0.4*	(0.3-0.7)	0.7*	(0.5-0.9)	0.7*	(0.5-0.9)	1.0	--	19.7*	1.2	(0.9-1.7)	1.1	(0.8-1.5)	1.1	(0.8-1.6)	1.0	--	1.8

Significant at the .05 level, two-sided test

¹Results are based on multivariable logistic regression models with dummy variables for survey and controls for the clinical variables in Table 2 as well as for respondent age, sex, and marital status. All respondents in the French survey were coded at the mean of education because education was not assessed in the French survey

Table 4. Subgroup associations of respondent education with 12-month treatment of mental disorders overall and in the specialty mental health and general medical sectors based on multivariable models that allowed for interactions of education with disorder severity and country income level controlling for clinical characteristics among WMH respondents with 12-month DSM-IV/CIDI disorders (n=16,753)¹

		Level of education								χ^2_3
		Low		Low-average		High-average		High		
		OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	
I. Any treatment										
A. Lower-middle-income countries										
Severe	2.0	(1.0-4.1)	1.2	(0.6-2.3)	1.4	(0.7-2.9)	1.0	--	4.1	
Moderate	0.9	(0.5-1.9)	1.4	(0.8-2.8)	0.8	(0.4-1.5)	1.0	--	4.0	
Mild	0.5	(0.2-1.1)	0.7	(0.3-1.6)	0.6	(0.3-1.3)	1.0	--	3.1	
B. Upper-middle-income countries										
Severe	0.7	(0.4-1.4)	0.7	(0.4-1.2)	0.9	(0.6-1.6)	1.0	--	2.2	
Moderate	0.8	(0.4-1.5)	0.7	(0.4-1.2)	0.7	(0.4-1.3)	1.0	--	2.3	
Mild	0.7	(0.4-1.4)	0.8	(0.4-1.4)	0.9	(0.6-1.5)	1.0	--	1.5	
C. High-income countries										
Severe	0.5*	(0.4-0.7)	0.7*	(0.5-1.0)	0.9	(0.7-1.2)	1.0	--	17.2*	
Moderate	0.7*	(0.5-0.9)	0.8*	(0.6-1.0)	0.8*	(0.6-1.0)	1.0	--	9.9*	
Mild	1.4	(1.0-1.9)	0.8	(0.6-1.1)	0.9	(0.7-1.2)	1.0	--	9.2*	
II. Specialty mental health treatment										
Total	0.6*	(0.5-0.8)	0.6*	(0.5-0.8)	0.7*	(0.6-0.9)	1.0	--	31.7*	
III. General medical treatment										
Total	1.0	(0.8-1.2)	1.0	(0.8-1.1)	1.0	(0.9-1.2)	1.0	--	0.4	

¹Significant at the .05 level, two-sided test

¹Results are based on three multivariable logistic regression models, one for each type of treatment. In each model, subgroup coding was used to estimate associations of education with the outcome in subgroups where the education-treatment outcome was found to be statistically different from in other subgroups. All models included dummy variables for survey, controls for the clinical variables in Table 2, and controls for respondent age, sex, marital status, and family income along with any significant interactions of income with disorder severity and country income level. All respondents in the French survey were coded at the mean of education because education was not assessed in the French survey.

Table 5. Subgroup associations of respondent family income with 12-month treatment of mental disorders overall and in the specialty mental health and general medical sectors based on multivariable models that allowed for interactions of education with disorder severity and country income level controlling for clinical characteristics among WMH respondents with 12-month DSM-IV/CIDI disorders (n=16,753)¹

Level of family income									
Low			Low-average		High-average		High		χ^2_3
OR	(95% CI)		OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	
I. Any treatment									
A. Lower-middle-income countries									
Severe	0.4*	(0.2-0.8)	0.2*	(0.1-0.4)	0.4*	(0.2-0.7)	1.0	--	20.1
Moderate	0.5*	(0.2-0.9)	0.8	(0.4-1.6)	1.0	(0.5-1.9)	1.0	--	7.4
Mild	1.6	(0.7-3.6)	1.0	(0.4-2.1)	0.8	(0.4-1.9)	1.0	--	2.5
B. Upper-middle-income countries									
Severe	0.7	(0.4-1.1)	1.0	(0.6-1.6)	1.0	(0.6-1.6)	1.0	--	4.0
Moderate	0.9	(0.5-1.5)	1.0	(0.6-1.7)	0.8	(0.5-1.3)	1.0	--	1.9
Mild	1.8*	(1.1-3.0)	0.7	(0.4-1.2)	1.3	(0.8-2.3)	1.0	--	14.9*
C. High-income countries									
Severe	1.0	(0.7-1.4)	1.2	(0.8-1.6)	0.8	(0.6-1.1)	1.0	--	6.4
Moderate	0.9	(0.7-1.2)	0.9	(0.7-1.2)	1.0	(0.8-1.3)	1.0	--	1.7
Mild	1.0	(0.7-1.4)	0.8	(0.6-1.1)	0.8	(0.6-1.1)	1.0	--	4.5
II. Specialty mental health (by severity regardless of country income level)									
Severe	0.7	(0.3-1.4)	0.5*	(0.3-0.8)	0.4*	(0.2-0.7)	1.0	--	10.9*
Moderate	0.7	(0.4-1.4)	0.4*	(0.3-0.8)	0.5*	(0.3-0.8)	1.0	--	11.2*
Mild	0.9	(0.4-1.9)	0.3*	(0.2-0.5)	0.4*	(0.2-0.7)	1.0	--	20.2*
III. General medical treatment									
A. Lower-middle-income countries									
Severe	0.6	(0.3-1.3)	0.5	(0.2-1.0)	0.9	(0.3-2.6)	1.0	--	4.5
Moderate	0.4*	(0.2-0.8)	0.5	(0.3-1.0)	0.8	(0.4-1.7)	1.0	--	8.8*
Mild	0.4*	(0.2-0.9)	0.2*	(0.1-0.8)	0.3*	(0.1-0.9)	1.0	--	11.0*
B. Upper-middle-income countries									
Severe	0.6	(0.4-1.1)	1.4	(0.8-2.6)	0.8	(0.5-1.5)	1.0	--	4.8
Moderate	0.8	(0.5-1.3)	1.4	(0.8-2.2)	0.6	(0.4-1.1)	1.0	--	6.7
Mild	1.7*	(1.1-2.5)	0.5	(0.3-1.0)	0.9	(0.5-1.5)	1.0	--	15.1*
C. High-income countries									
Severe	1.8*	(1.4-2.3)	2.0*	(1.6-2.6)	1.5*	(1.2-2.0)	1.0	--	44.3*
Moderate	1.0	(0.8-1.3)	1.0	(0.8-1.2)	1.1	(0.9-1.3)	1.0	--	1.0
Mild	0.8	(0.6-1.1)	0.6*	(0.5-0.8)	0.7*	(0.5-0.9)	1.0	--	18.3*

*Significant at the .05 level, two-sided test

¹Results are based on three multivariable logistic regression models, one for each type of treatment. In each model, subgroup coding was used to estimate associations of family income with the outcome in subgroups where the income-treatment outcome was found to be statistically different from in other subgroups. All models included dummy variables for survey, controls for the clinical variables in Table 2, and controls for respondent age, sex, marital status, and respondent education along with any significant interactions of education with disorder severity and country income level. All respondents in the French survey were coded at the mean of education because education was not assessed in the French survey

Appendix Table 1. WMH sample characteristics by World Bank income categories^a

					Sample size			
Country by income category	Survey ^b	Sample characteristics ^c	Field dates	Age range	Part I	Part II	Part II and age ≤ 44 ^d	Response rate ^e
I. Low and lower middle income countries								
Colombia	NSMH	All urban areas of the country (approximately 73% of the total national population)	2003	18-65	4,426	2,381	1,731	87.7
Iraq	IMHS	Nationally representative.	2006-7	18-96	4,332	4,332	--	95.2
Nigeria	NSMHW	21 of the 36 states in the country, representing 57% of the national population. The surveys were conducted in Yoruba, Igbo, Hausa and Efik languages.	2002-3	18-100	6,752	2,143	1,203	79.3
PRC ^f - Beijing/Shanghai	B-WMH/S-WMH	Beijing and Shanghai metropolitan areas.	2002-3	18-70	5,201	1,628	570	74.7
PRC ^f - Shenzhen ^g	Shenzhen	Shenzhen metropolitan area. Included temporary residents as well as household residents.	2006-7	18-88	7,132	2,475	--	80.0
Peru	EMSMP	Five urban areas of the country (approximately 38% of the total national population).	2004-5	18-65	3,930	1,801	1,287	90.2
Ukraine	CMDPSD	Nationally representative.	2002	18-91	4,725	1,720	541	78.3
TOTAL					(36,498)	(16,480)	(5,332)	82.2
II. Upper-middle income countries								
Brazil - São Paulo	São Paulo Megacity	São Paulo metropolitan area.	2005-7	18-93	5,037	2,942	--	81.3
Bulgaria	NSHS	Nationally representative.	2003-7	18-98	5,318	2,233	741	72.0
Colombia - Medellin ^h	MMHHS	Medellin metropolitan area	2011-12	19-65	3,261	1,673		97.2
Lebanon	LEBANON	Nationally representative.	2002-3	18-94	2,857	1,031	595	70.0
Mexico	M-NCS	All urban areas of the country (approximately 75% of the total national population).	2001-2	18-65	5,782	2,362	1,736	76.6
Romania	RMHS	Nationally representative.	2005-6	18-96	2,357	2,357	--	70.9
South Africa ^g	SASH	Nationally representative.	2003-4	18-92	4,315	4,315	--	87.1
TOTAL					(28,927)	(16,913)	(3,072)	78.5
III. High-income countries								
Belgium	ESEMeD	Nationally representative. The sample was selected from a national register of Belgium residents	2001-2	18-95	2,419	1,043	486	50.6
France	ESEMeD	Nationally representative. The sample was selected from a national list of households with listed telephone numbers.	2001-2	18-97	2,894	1,436	727	45.9
Germany	ESEMeD	Nationally representative.	2002-3	19-95	3,555	1,323	621	57.8
Israel	NHS	Nationally representative.	2002-4	21-98	4,859	4,859	--	72.6
Italy	ESEMeD	Nationally representative. The sample was selected from municipality resident registries.	2001-2	18-100	4,712	1,779	853	71.3
Japan	WMHJ 2002-2006	Eleven metropolitan areas.	2002-6	20-98	4,129	1,682	--	55.1
Netherlands	ESEMeD	Nationally representative. The sample was selected from municipal postal registries.	2002-3	18-95	2,372	1,094	516	56.4
New Zealand ^g	NZMHS	Nationally representative.	2003-4	18-98	12,790	7,312	--	73.3
N. Ireland	NISHS	Nationally representative.	2004-7	18-97	4,340	1,986	--	68.4
Poland	EZOP	Nationally representative	2010-11	18-65	10,081	4,000	2,276	50.4

Portugal	NMHS	Nationally representative.	2008-9	18-81	3,849	2,060	1,070	57.3
Spain	ESEMeD	Nationally representative.	2001-2	18-98	5,473	2,121	960	78.6
Spain - Murcia	PEGASUS-Murcia	Murcia region. Regionally representative.	2010-12	18-96	2,621	1,459	--	67.4
United States	NCS-R	Nationally representative.	2002-3	18-99	9,282	5,692	3,197	70.9
TOTAL					(73,376)	(37,846)	(10,706)	62.9
IV. TOTAL					(138,801)	(71,239)	(19,110)	70.1

Appendix Table 2. Within-survey distributions and associations (polychoric correlations) between level of education and level of family income among WMH respondents with 12-month DSM-IV/CIDI disorders (n = 16,753) 818

	Level of education ¹				Level of family income ²				r ^{*2}
	Low	Low-average	High	High-average	Low	Low-average	High	High-average	
	% (SE)	% (SE)	% (SE)	% (SE)	% (SE)	% (SE)	% (SE)	% (SE)	
I. Lower-middle income countries									
Colombia	30.0 (2.5)	29.3 (2.6)	19.5 (1.6)	21.2 (2.5)	35.2 (2.9)	24.8 (2.8)	16.6 (1.9)	23.3 (2.7)	0.405*
Iraq	20.6 (3.2)	36.9 (3.8)	32.5 (3.2)	10.1 (1.8)	27.0 (3.0)	24.8 (2.8)	23.1 (2.7)	22.7 (3.9)	0.269*
Nigeria	19.5 (3.7)	21.3 (4.6)	43.1 (4.6)	16.1 (4.5)	39.7 (5.4)	15.7 (3.5)	18.6 (4.5)	26.0 (4.2)	0.284*
PRC-Beijing/Shanghai	16.4 (5.6)	21.1 (3.8)	39.7 (5.3)	22.8 (5.0)	21.4 (4.4)	33.9 (6.0)	27.4 (5.2)	17.3 (4.5)	0.328*
PRC-Shenzhen	1.9 (0.8)	19.6 (3.0)	40.6 (3.9)	37.9 (3.1)	29.9 (2.9)	18.8 (2.4)	21.6 (2.9)	29.7 (3.9)	0.389*
Peru	13.4 (1.8)	11.0 (2.0)	58.9 (3.1)	16.6 (2.8)	37.3 (2.6)	21.1 (2.4)	20.0 (2.4)	21.5 (3.8)	0.519*
Ukraine	17.3 (2.4)	52.9 (2.7)	14.6 (2.7)	15.2 (2.3)	18.2 (2.3)	35.2 (2.9)	34.5 (2.8)	12.1 (2.5)	0.192*
Overall	19.4 (1.2)	31.3 (1.3)	31.0 (1.3)	18.3 (1.0)	29.5 (1.2)	26.1 (1.2)	22.9 (1.1)	21.5 (1.4)	0.324*
II. Upper-middle income countries									
Brazil-Sao Paulo	24.2 (1.6)	24.7 (1.5)	35.4 (1.8)	15.6 (2.0)	25.3 (1.8)	27.3 (2.0)	23.8 (1.7)	23.6 (2.6)	0.419*
Bulgaria	10.3 (2.1)	23.0 (3.0)	41.8 (4.0)	25.0 (4.3)	16.9 (2.1)	30.2 (3.3)	27.6 (3.1)	25.3 (4.4)	0.389*
Colombia-Medellin	2.1 (0.6)	22.2 (2.4)	48.0 (3.0)	27.8 (2.9)	41.7 (3.0)	18.1 (2.3)	20.8 (2.4)	19.5 (2.5)	0.211*
Lebanon	21.2 (4.8)	33.4 (3.9)	28.7 (5.0)	16.7 (3.3)	29.0 (4.2)	21.7 (4.2)	17.1 (4.8)	32.2 (4.5)	0.240*
Mexico	20.7 (2.3)	23.0 (2.2)	29.5 (2.4)	26.7 (2.8)	29.9 (2.8)	27.3 (2.2)	19.4 (1.8)	23.4 (2.0)	0.393*
Romania	10.9 (2.2)	21.1 (2.6)	51.9 (3.1)	16.1 (2.9)	32.0 (4.5)	17.0 (3.7)	20.9 (3.3)	30.1 (4.5)	0.234*
South Africa	6.1 (1.1)	23.1 (2.1)	54.7 (2.4)	16.2 (2.0)	41.7 (3.2)	10.2 (1.3)	11.6 (1.7)	36.4 (3.3)	0.329*
Overall	14.4 (0.8)	24.0 (0.8)	42.3 (1.1)	19.3 (0.9)	31.8 (1.0)	21.1 (0.8)	19.5 (0.9)	27.7 (1.1)	0.313*
III. High income countries									
Belgium	10.0 (2.3)	13.1 (2.8)	49.4 (5.3)	27.4 (4.3)	22.5 (4.6)	25.7 (3.4)	36.4 (5.1)	15.4 (2.6)	0.127*
France	-- --	-- --	-- --	-- --	30.0 (4.4)	31.5 (3.7)	24.1 (2.7)	14.4 (2.9)	--
Germany	23.5 (4.2)	32.1 (4.8)	39.5 (6.4)	4.9 (2.4)	26.1 (3.9)	28.5 (4.0)	30.7 (3.6)	14.8 (2.6)	-0.030
Israel	27.4 (2.1)	40.6 (2.4)	12.6 (1.6)	19.4 (1.9)	32.4 (2.3)	27.9 (2.2)	27.9 (2.1)	11.9 (1.5)	0.399*
Italy	31.9 (4.3)	17.1 (2.7)	33.6 (3.5)	17.4 (3.4)	22.6 (3.4)	25.6 (2.7)	32.8 (3.8)	19.0 (4.2)	0.184*
Japan	15.4 (2.4)	29.9 (3.5)	28.2 (3.7)	26.5 (4.1)	31.1 (3.9)	24.1 (3.3)	31.1 (3.5)	13.7 (2.1)	-0.023
Netherlands	23.8 (3.9)	41.4 (4.5)	9.7 (1.8)	25.1 (3.4)	30.8 (5.6)	25.0 (3.3)	30.6 (3.6)	13.5 (2.5)	0.366*
New Zealand	19.7 (1.1)	22.7 (1.0)	29.5 (1.3)	28.1 (1.4)	26.2 (1.4)	30.5 (1.2)	28.2 (1.3)	15.1 (1.0)	0.261*
Northern Ireland	4.7 (1.0)	9.5 (1.6)	70.9 (2.7)	14.8 (2.1)	28.6 (2.8)	25.2 (2.9)	25.4 (1.9)	20.9 (3.0)	0.153**
Poland	10.9 (1.6)	3.5 (1.1)	67.7 (2.2)	17.9 (2.0)	41.5 (2.6)	12.9 (1.6)	24.1 (2.0)	21.6 (2.0)	0.217**
Portugal	20.9 (1.6)	33.0 (2.0)	26.7 (2.2)	19.5 (1.7)	31.3 (2.4)	16.8 (1.8)	25.5 (2.7)	26.5 (2.3)	0.357**
Spain	22.0 (3.1)	34.1 (4.4)	16.8 (2.7)	27.1 (4.6)	24.5 (4.5)	26.0 (4.6)	30.9 (3.9)	18.6 (3.2)	0.219**
Spain-Murcia	23.0 (3.3)	35.2 (4.0)	21.5 (2.8)	20.3 (3.8)	31.2 (4.2)	32.3 (3.1)	25.0 (2.8)	11.5 (2.4)	0.198**
USA	18.4 (1.3)	32.9 (2.3)	29.0 (1.3)	19.7 (1.5)	30.3 (1.7)	25.4 (1.2)	26.0 (1.4)	18.3 (1.4)	0.434**
Overall	18.0 (0.5)	25.5 (0.7)	35.7 (0.7)	20.7 (0.6)	29.5 (0.7)	26.0 (0.6)	27.3 (0.7)	17.2 (0.5)	0.280**
Total	17.4 (0.4)	26.1 (0.5)	36.6 (0.6)	19.9 (0.5)	30.1 (0.5)	24.8 (0.5)	24.5 (0.5)	20.6 (0.5)	0.295**

*Significant at the .05 level, two-sided test

¹See the text for a description of the coding rules for the categorical measures of education and income.

²Polychoric correlations

³All respondents in the French survey were coded at the mean value of the education distribution across other surveys because education was not assessed in the French survey.